Literature DB >> 28120401

Mucocutaneous toxicity during simeprevir treatment for hepatitis C. A single institution, retrospective case series.

Francesco Borgia1, Irene Cacciola1, Roberto Filomia1, Mario Vaccaro1, Giovanni Squadrito1, Serafinella P Cannavò1.   

Abstract

Entities:  

Keywords:  HCV protease inhibitors; mucocutaneous toxicity; photosensitivity; simeprevir

Mesh：

Substances：

Year:  2017        PMID： 28120401      PMCID： PMC6396847          DOI： 10.1111/bcp.13221

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  7 in total

1.  Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.

Authors:  M P Manns; M W Fried; S Zeuzem; I M Jacobson; X Forns; F Poordad; M Peeters; M Fu; O Lenz; S Ouwerkerk-Mahadevan; W Jessner; J A Scott; R Kalmeijer; G De La Rosa; R Sinha; M Beumont-Mauviel
Journal:  J Viral Hepat       Date:  2014-11-03       Impact factor: 3.728

Review 2.  Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.

Authors:  Patrice Cacoub; Marc Bourlière; Jann Lübbe; Nicolas Dupin; Peter Buggisch; Geoffrey Dusheiko; Christophe Hézode; Odile Picard; Ramon Pujol; Siegfried Segaert; Bing Thio; Jean-Claude Roujeau
Journal:  J Hepatol       Date:  2011-08-30       Impact factor: 25.083

3.  Photo-distributed lichenoid eruption secondary to direct anti-viral therapy for hepatitis C.

Authors:  Cory L Simpson; Drew McCausland; Emily Y Chu
Journal:  J Cutan Pathol       Date:  2015-07-03       Impact factor: 1.587

4.  Biphasic skin reactions during telaprevir-based therapy of Japanese patients infected with hepatitis C virus.

Authors:  Akiko Kishi; Nobukazu Hayashi; Kuniaki Ohara; Keiji Aoki; Ichimaro Yamada; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Am Acad Dermatol       Date:  2014-03       Impact factor: 11.527

Review 5.  Development of sofosbuvir for the treatment of hepatitis C virus infection.

Authors:  Eric Lawitz; Ira M Jacobson; David R Nelson; Stefan Zeuzem; Mark S Sulkowski; Rafael Esteban; Diana Brainard; John McNally; William T Symonds; John G McHutchison; Douglas Dieterich; Edward Gane
Journal:  Ann N Y Acad Sci       Date:  2015-07-31       Impact factor: 5.691

6.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

Authors:  Eric Lawitz; Mark S Sulkowski; Reem Ghalib; Maribel Rodriguez-Torres; Zobair M Younossi; Ana Corregidor; Edwin DeJesus; Brian Pearlman; Mordechai Rabinovitz; Norman Gitlin; Joseph K Lim; Paul J Pockros; John D Scott; Bart Fevery; Tom Lambrecht; Sivi Ouwerkerk-Mahadevan; Katleen Callewaert; William T Symonds; Gaston Picchio; Karen L Lindsay; Maria Beumont; Ira M Jacobson
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

7.  Photo-induced drug eruption in a patient on combination simeprevir/sofosbuvir for hepatitis C.

Authors:  Zachary W Eyre; Aaron M Secrest; Jamie L Woodcock
Journal:  JAAD Case Rep       Date:  2016-05-31
  7 in total
  1 in total

Review 1.  Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review.

Authors:  Paul C Macklis; Brittany Dulmage; Brady Evans; Misha Rosenbach; Johann E Gudjonsson; Benjamin H Kaffenberger
Journal:  Drugs R D       Date:  2020-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.